Rating Change
Bernstein analysts downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from Outperform to Market Perform on October 30, 2026.
downgradeNASDAQ:ALNY
Alnylam Pharmaceuticals, Inc. (ALNY) Downgraded to Market Perform by Bernstein
Bernstein analysts downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from Outperform to Market Perform on October 30, 2026.
At publication ·
What changed
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) · downgrade
- Firm
- Bernstein
- Rating
- Outperform to Market Perform
- Price at event
- $165.00
- Market capitalization
- $44.2B
At a glance
Key takeaways
- Bernstein downgraded Alnylam Pharmaceuticals from Outperform to Market Perform on October 30, 2026.
- The stock has declined 65.7% over the past 52 weeks and currently trades at $165.00 with a $44.2B market capitalization.
- Among the 10 most recent analyst ratings, 6 are Buy, 4 are Hold, and 0 are Sell, showing mixed sentiment despite the downgrade.
Market Context
Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $165.00 with a market capitalization of $44.2B. The stock has declined 65.7% over the past 52 weeks.
Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Bernstein's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Alnylam Pharmaceuticals, Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 30, 2026 | RBC Capital | Outperform | N/A |
| Oct 30, 2026 | Wells Fargo | Equal-Weight | N/A |
| Oct 30, 2026 | Goldman Sachs | Buy | N/A |
| Oct 30, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Oct 30, 2026 | Bernstein | Market Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View ALNY Stock Page
Frequently Asked Questions
What does the Market Perform rating mean for ALNY?
A rating of Market Perform from Bernstein reflects the analyst's outlook on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ALNY forecast page.
Loading related coverage…